KIMBERLY MANHARD
CIK 1202094 · EVP, Drug Development · last filed 2026-06-04
KIMBERLY MANHARD is an EVP, Drug Development who has filed 86 SEC Form 4 insider transactions across 4 companies since 2008. The most recent filing, for INBX, was dated Jun 4, 2026. Across all open-market trades the lifetime net is −$6.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $933.3K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$933.3K
4
86
-$6.42M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| INBX | Director | 10,000 | $92.20 | $922.0K | $139.8K | 7 | 2026-06-04 |
| Inhibrx, Inc. (INBXV) Delisted | Director | — | — | — | $0 | 1 | 2024-05-30 |
| HRTX | EVP, Drug Development | 28,330 | $0.40 | $11.3K | -$2.65M | 33 | 2023-04-17 |
| Ardea Biosciences, Inc./DE (RDEA) Delisted | SVP, Regulatory & Dev Ops | 0 | — | — | -$3.90M | 43 | 2012-06-20 |
Recent Filings
86 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-04 | INBX | Grant (A) | — | $0 | EDGAR |
| 2025-05-29 | INBX | Grant (A) | — | $0 | EDGAR |
| 2024-08-30 | INBX | Buy (P) | +10,000 | $139.8K | EDGAR |
| 2024-05-30 | — | Grant (A) | — | $0 | |
| 2024-05-30 | Inhibrx, Inc. (INBXV) Delisted | Disp (D) | — | $0 | EDGAR |
| 2023-05-30 | INBX | Grant (A) | — | $0 | EDGAR |
| 2023-04-17 | HRTX | Mixed | +4,397 | -$4.1K | EDGAR |
| 2023-01-20 | HRTX | Grant (A) | — | $0 | EDGAR |
| 2023-01-17 | HRTX | Mixed | +5,457 | -$962 | EDGAR |
| 2022-10-17 | HRTX | Mixed | +3,802 | -$7.6K | EDGAR |